Status:

RECRUITING

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

Lead Sponsor:

Vanderbilt University Medical Center

Conditions:

Type 1 Diabetes Mellitus

Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)

Eligibility:

All Genders

18-60 years

Phase:

EARLY_PHASE1

Brief Summary

This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at ...

Eligibility Criteria

Inclusion

  • Age: 18-60 years BMI: 18-28 kg/m² Weight: ≥ 50 kg
  • T1DM Participants:
  • Duration of T1DM: 1-30 years HbA1c: 5.7-7.5% Insulin Therapy: Using automated insulin delivery
  • GCK-MODY Participants:
  • HbA1c: 5.7-7.5% Genetic Confirmation: Positive GCK sequencing
  • Control Participants:
  • HbA1c: less than 5.5%
  • \*\*

Exclusion

  • Severe Hypoglycemia: ≥1 episode in the past 3 months
  • Comorbidities:
  • Any hospital admissions for diabetic ketoacidosis in the past 6 months
  • SBP greater than 140 mmHg and DBP greater than 100 mmHg
  • eGFR by MDRD equation of less than 60 mL/min/1.73 m²
  • AST or ALT greater than 2.5 times ULN
  • Hct less than 35%
  • Medications:
  • Any antioxidant vitamin supplement within 2 weeks before the study
  • Any systemic glucocorticoid
  • Antipsychotics
  • Atenolol, Metoprolol, Propranolol
  • Niacin
  • Any thiazide diuretic
  • Any oral contraceptive pill with greater than 35 mcg ethinyl estradiol
  • Growth hormone
  • Any immunosuppressant
  • Antihypertensive
  • Any antihyperlipidemic
  • Other:
  • Pregnancy
  • Tanner stage less than 5
  • Peri- or post-menopausal women
  • Active smoker
  • T1DM Participants:
  • Medications: Any diabetes medication except insulin C-peptide: greater than 0.7 ng/mL (fasting)
  • GCK-MODY Participants:
  • None specific

Key Trial Info

Start Date :

July 3 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT06609356

Start Date

July 3 2025

End Date

December 1 2027

Last Update

December 23 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232